Uniqure Nv Stock Quote 0EE0 - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

31.50

Bid

0.00

Ask

0.00

Volume

423

0.00 Day's Range 0.00

31.50 52 Week Range 31.50

Market Cap

223.863M

Previous Close

31.50

Open

Last Trade

4.87

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

1,140

Shares Outstanding

47,834,000

Dividend Yield

PE Ratio

-0.73

Earnings Per Share (EPS)

-6.45

Revenue

21.9M

Net Profit

-308.48M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.uniqure.com

Headquarters

Amsterdam, North Holland, Nld

Founded

1970

Uniqure Nv is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0EE0. The last closing price for Uniqure Nv was $31.50. Over the last year, Uniqure Nv shares have traded in a share price range of $ 31.50 to $ 31.50.

Uniqure Nv currently has 47,834,000 shares outstanding. The market capitalization of Uniqure Nv is $223.86 million. Uniqure Nv has a price to earnings ratio (PE ratio) of -0.73.

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress ~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease;...

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease ~ Patients treated with AMT-130 continue to show evidence of preserved...

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene...

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease Patient enrollment expected to begin in first half of 2024LEXINGTON, Mass...

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress ~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory...

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V...

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs ~ Reduction of 28% of workforce not related to HEMGENIX®...

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene...

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy Clinical trial initiation expected in the fourth...

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress ~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130...

Period	Open	High	Low	Avg. Daily Vol	VWAP
1	31.5	31.5	31.5	967	31.5	DE
4	31.5	31.5	31.5	550	31.5	DE
12	31.5	31.5	31.5	1140	31.5	DE
26	31.5	31.5	31.5	1462	31.5	DE
52	31.5	31.5	31.5	1348	31.5	DE
156	31.5	31.5	31.5	1175	31.5	DE
260	31.5	31.5	31.5	913	31.5	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BENFBeneficient	$ 6.8001 (254.17%)	31.01M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M
SHOTWSafety Shot Inc	$ 0.45 (45.16%)	644
AIPArteris Inc	$ 8.185 (38.03%)	1.11M
RGFReal Good Food Company Inc	$ 0.85 (37.32%)	4.26M
MNDRMobile health Network Solutions	$ 3.33 (-84.91%)	18.76M
NUVOHoldco Nuvo Group DG Ltd	$ 2.00 (-57.54%)	1.04M
SPTSprout Social Inc	$ 28.82 (-40.15%)	13.47M
UNITUniti Group Inc	$ 4.441 (-26.35%)	21.07M
IPDNProfessional Diversity Network Inc	$ 1.29 (-24.12%)	662.59k
AAPLApple Inc	$ 183.38 (5.98%)	163.22M
SQQQProShares UltraPro Short QQQ	$ 11.08 (-5.94%)	154.59M
JAGXJaguar Health Inc	$ 0.3164 (7.91%)	142.47M
NKLANikola Corporation	$ 0.6526 (6.55%)	106.88M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M